The goal of the Centralized Histopathology Laboratory (CHPL) is to provide histologic services to investigators at M.D. Anderson Cancer Center. The CHPL supplies technical support and consultation, develops or applies appropriate techniques, and maintains the consistency and high quality needed to perform these techniques. The CHPL is currently located in the Department of Pathology in 375 feet/2. Because of the increasing emphasis on in vivo systems in cancer biology and developmental biology, the number of laboratories using tissue specimens, transgenic mice, and gene-knockout technologies has increased dramatically. To provide efficient histology services to the institution, the CHPL will be expanded, and a second 370- feet/2 laboratory will be located in the R.E. """"""""Bob"""""""" Smith Research Building. The well-equipped and well-staffed CHPL processes fixed and frozen specimens for routine histologic analysis, immunohistochemical in situ hybridization (colorimetric procedures), and special staining for tissue sections and cells. The CHPL (both sites) is directed by Dr. Isaiah J. Fidler, and is accessible to all faculty, at M.D. Anderson Cancer Center, will preference given to investigators with peer-reviewed grants. Among the services provided are rapid preparation of high-quality standard histologic sections; application of special technologies as the need arises for selected projects, including preparation of frozen sections and histochemical, immunohistochemical, and tissue sections for in situ hybridization analysis; consultation with investigators to tailor technology to their special needs; and interpretation of histologic data. To access the CHPL, investigators make a formal application. After approval by the Director, the histotechnologist meets with the investigators to determine special needs of the study and the technical staff provides the histopathological services. The services are prioritized and coordinated to provide timely service. The development of new technologies that require additional equipment or special supplies has been funded by M.D. for specialized procedures such as in situ hybridization and 500 specially stained slides yearly. The increase in studies of transgenic mice and gene knockout mice will significantly increase the CHPL's workload, especially for special preparations such as serial sections of whole-embryos mounts. The CHPL is an essential component of the M.D. Anderson centralized research facilities that require histologic analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-25S1
Application #
6347264
Study Section
Project Start
2000-08-30
Project End
2001-06-30
Budget Start
Budget End
Support Year
25
Fiscal Year
2000
Total Cost
$254,104
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Luo, Yangkun; Xu, Yujin; Liao, Zhongxing et al. (2018) Automatic segmentation of cardiac substructures from noncontrast CT images: accurate enough for dosimetric analysis? Acta Oncol :1-7
Zhao, Na; Cao, Jin; Xu, Longyong et al. (2018) Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. J Clin Invest 128:1283-1299
Liu, Yihua; Weber, Zachary; San Lucas, F Anthony et al. (2018) Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas. Gynecol Oncol 151:243-249
Joint Head and Neck Radiotherapy-MRI Development Cooperative (2018) Dynamic contrast-enhanced magnetic resonance imaging for head and neck cancers. Sci Data 5:180008
Jensen, Garrett; Tao, Randa; Eng, Cathy et al. (2018) Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation. Adv Radiat Oncol 3:595-600
Staffas, Anna; Burgos da Silva, Marina; Slingerland, Ann E et al. (2018) Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice. Cell Host Microbe 23:447-457.e4
Boddu, Prajwal; Borthakur, Gautam; Koneru, Mythili et al. (2018) Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol 8:369
Takahashi, Nobuaki; Chen, Hsing-Yu; Harris, Isaac S et al. (2018) Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. Cancer Cell 33:985-1003.e7
Garg, Rachana; Blando, Jorge M; Perez, Carlos J et al. (2018) COX-2 mediates pro-tumorigenic effects of PKC? in prostate cancer. Oncogene 37:4735-4749
Flinn, Ian W; O'Brien, Susan; Kahl, Brad et al. (2018) Duvelisib, a novel oral dual inhibitor of PI3K-?,?, is clinically active in advanced hematologic malignancies. Blood 131:877-887

Showing the most recent 10 out of 12418 publications